ABSTRACT
Skeletal system is the most common metastasis site in patients with advanced cancer. Pain is an important health problem in patients with bone metastasis. Bone seeking radionuclides to treat bone pain due to bone metastasis in patients with advanced stage cancer can be used in selected group of cancer patients. In this review, evaluating patients who might be candidates for radionuclide treatment of bone metastases using beta-emitting radionuclides such as strontium-89, samarium-153 lexidronam, phosphor-32 sodium phosphate, Lutetium-177 ethylenediaminetetramethylene phosphonic acid and alfa-emmiting Radium-223, performing the treatments; and understanding and evaluating the treatment outcome and side effects.
References
1Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987;55:61-66.
2Levy MH. Pharmacologic treatment of cancer pain. N Engl J Med. 1996;335:1124-1132.
3Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain. 1997;69:1-18.
4Nielsen OS, Munro AJ, Tannock IF. Bone metastases: pathophysiology and management policy. J Clin Oncol. 1991;9:509-524.
5Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213-223.
6Poeppel TD, Handkiewicz-Junak D, Andreeff M, et al. EANM Guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017;45:824-845.
7Handkiewicz-Junak D, Poeppel TD, Bodei L. et al. EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides. Eur J Nucl Med Mol Imaging. 2018;45:846-859.
8Lewington VJ, McEwan AJ, Ackery DM, et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer. 1991;27:954-958.
9Fuster D, Herranz D, Vidal-Sicart S, et al. Usefulness of strontium-89 for bone pain palliation in metastatic breast cancer patients. Nucl Med Commun. 2000;21:623-626.
10Kraeber-Bodéré F, Campion L, Rousseau C, Bourdin S, Chatal JF, Resche I. Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement. Eur J Nucl Med. 2000;27:1487-1493.
11Turner SL, Gruenewald S, Spry N, Gebski V. Metastron users group. Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer. Br J Cancer. 2001;84:297-302.
12 Dafermou A, Colamussi P, Giganti M, Cittanti C, Bestagno M, Piffanelli A. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur J Nucl Med. 2001;28:788-798.
13Ashayeri E, Omogbehin A, Sridhar R, Shankar RA. Strontium 89 in the treatment of pain due to diffuse osseous metastases: a university hospital experience. J Natl Med Assoc. 2002;94:706-711.
14Zorga P, Birkenfeld B. Strontium-89 in palliative treatement of painfull bone metastases. Ortop Traumatol Rehabil. 2003;5:369-373.
15Baczyk M, Milecki P, Baczyk E, Sowinski J. The effectiveness of strontium 89 in palliative therapy of painful prostate cancer bone metastases. Ortop Traumatol Rehabil. 2003;5:364-368.
16Oosterhof GO, Roberts JT, de Reijke TM, et al. Strontium (89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur Urol. 2003;44:519-526.
17Gunawardana DH, Lichtenstein M, Better N, Rosenthal M. Results of strontium-89 therapy in patients with prostate cancer resistant to chemotherapy. Clin Nucl Med. 2004;29:81-85.
18Liepe K, Kotzerke J. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun. 2007;28:623-630.
19Zenda S, Nakagami Y, Toshima M, et al. Strontium-89 (Sr-89) chloride in the treatment of various cancer patients with multiple bone metastases. Int J Clin Oncol. 2014;19:739-743.
20Collins C, Eary JF, Donaldson G, et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med. 1993;34:1839-1844.
21Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol. 1998;16:1574-1581.
22Tian JH, Zhang JM, Hou QT, et al. Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China. Eur J Nucl Med. 1999;26:2-7.
23Dolezal J. Systemic radionuclide therapy with samarium-153-EDTMP for painful bone metastases. Nucl Med Rev Cent East Eur. 2000;3:161-163.
24Wang RF, Zhang CL, Zhu SL, Zhu M. A comparative study of samarium-153-ethylenediaminetetramethylene phosphonic acid with pamidronate disodium in the treatment of patients with painful metastatic bone cancer. Med Princ Pract. 2003;12:97-101.
25Sapienza MT, Ono CR, Guimarães MI, Watanabe T, Costa PA, Buchpiguel CA. Retrospective evaluation of bone pain palliation after samarium-153-EDTMP therapy. Rev Hosp Clin Fac Med Sao Paulo. 2004;59:321-328.
26Etchebehere EC, Pereira Neto CA, Lima MC, et al. Treatment of bone pain secondary to metastases using samarium-153-EDTMP. Sao Paulo Med J. 2004;122:208-212.
27Sartor O, Reid RH, Hoskin PJ, et al. Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004;63:940-945.
28Tripathi M, Singhal T, Chandrasekhar N, et al. Samarium-153 ethylenediamine tetramethylene phosphonate therapy for bone pain palliation in skeletal metastases. Indian J Cancer. 2006;43:86-92.
29 Ripamonti C, Fagnoni E, Campa T, Seregni E, Maccauro M, Bombardieri E. Incident pain and analgesic consumption decrease after samarium infusion: a pilot study. Support Care Cancer. 2007;15:339-342.
30Olea E, Gil MC, Tomicic M, et al. Nationally produced 153SmEDTMP in the palliative treatment of metastatic bone cancer pain. Rev Med Chil. 1996;124:805-812.
31Krishnamurthy GT, Krishnamurthy S. Radionuclides for metastatic bone pain palliation: a need for rational re-evaluation in the new millennium. J Nucl Med. 2000;41:688-691.
32Edwards GK, Santoro J, Taylor AJR. Use of bone scintigraphy to select patients with multiple myeloma for treatment with strontium-89. J Nucl Med. 1994;35:1992-1993.
33Farhanghi M, Holmes RA, Volkert WA, Logan KW, Singh A. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med. 1992;33:1451-1458.
34De Klerk JM, Zonnenberg BA, Blijham GH, et al. Treatment of metastatic bone pain using the bone seeking radiopharmaceutical re-186-HEDP. Anticancer Res. 1997;17:1773-1377.
35Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol. 2005;6:392-400.
36Taylor Jr AJ. Strontium-89 for the palliation of bone pain due to metastatic disease. J Nucl Med. 1994;35:2054.
37D’Angelo G, Sciuto R, Salvatori M, et al. Targeted “bone-seeking” radiopharmaceuticals for palliative treatment of bone metastases: a systematic review and meta-analysis. Q J Nucl Med Mol Imaging. 2012;56:538-543.
38Roque M, Martinez MJ, Alonso P, Catala E, Garcia JL, Ferrandiz M. Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev. 2003;4:CD003347.
39Bauman G, Charette M, Reid R, Sathya J. Radiopharmaceuticals for the palliation of painful bone metastasis - a systemic review. Radiother Oncol. 2005;75:258-270.
40Christensen MH, Petersen LJ. Radionuclide treatment of painful bone metastases in patients with breast cancer: a systematic review. Cancer Treat Rev. 2012;38:164-171.
41 Nilsson S, Strang P, Aksnes AK, et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer. 2012;48:678-686.
42Porter AT, McEwan AJ, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993;25:805-813.
43Kurosaka S, Satoh T, Chow E, et al. EORTC QLQ-BM22 and QLQ-C30 quality of life scores in patients with painful bone metastases of prostate cancer treated with strontium-89 radionuclide therapy. Ann Nucl Med. 2012;26:485-491.
44Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001;357:336-341..
45Resche I, Chatal JF, Pecking A, et al. A dose-controlled study of 153Sm- ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer. 1997;33:1583-1591.
46Paszkowski AL, Hewitt DJ, Taylor AJR. Disseminated intravascular coagulation in a patient treated with strontium-89 for metastatic carcinoma of the prostate. Clin Nucl Med. 1999;24:852-854.
47Silberstein EB, Williams C. Strontium-89 therapy for the pain of osseous metastases. J Nucl Med. 1985;26:345-348.
48Pillai MR, Chakraborty S, Das T, Venkatesh M, Ramamoorthy N. Production logistics of Lu-177 for radionuclide therapy. Appl Radiat Isot. 2003;59:109-118.
49Chakraborty S, Das T, Banerjee S, et al. Lu-177 EDTMP: a viable bone pain palliative in skeletal metastasis. Cancer Biother Radiopharm. 2008;23:202-213.
50Yuan J, Liu C, Liu X, et al. Efficacy and safety of Lu-177 EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a phase II study. Clin Nucl Med. 2013;38:88-92.
51Nilsson S, Larsen RH, Foss SD, et al. First clinical experience with α-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005;11:4451-4459.
52Ritter MA, Cleaver JE, Tobias CA. High-LET radiations induce a large proportion of non-rejoining DNA breaks. Nature 1977;266:653-655.
53Lassmann M, Nosske D. Dosimetry of 223Ra-chloride: dose to normal organs and tissues. Eur J Nucl Med Mol Imaging 2013;40:207-212.
54Bruland OS, Nilsson S, Fisher DR, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res 2006;12:6250-6257.
55Saad F, Carles J, Gillessen S, et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol 2016;17:1306-1316.
56Hoskin P, Sartor O, O’Sullivan JM, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous dosetaksel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol 2014;15:1397-1406.
57Nilsson S, Cislo P, Sartor O, et al. Patient-reported quality of life analysis of radium-223 dichloride from the phase 3 ALSYMPCA study. Ann Oncol 2016;27:868-874.
58Sartor O, Hoskin P, Coleman RE, et al. Chemotherapy following radium-223 dichloride treatment in ALSYMPCA. Prostate 2016;76:905-916.
